CLCN1 and Myotonia: In 2018, mexiletine was approved for the symptomatic treatment of non-dystrophic myotonia (paramyotonia congenita and myotonia congenita) [12] caused by mutations in chloride (CLCN1) and skeletal muscle voltage-gated sodium (SCN4A) channels [47].